ReviewCellular and molecular life sciences : CMLS2025
From smog to scarred hearts: unmasking the detrimental impact of air pollution on myocardial ischemia-reperfusion injury.
Review in Cellular and molecular life sciences : CMLS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Training Community-Academic Teams to Use Low-Cost Air Monitors: A Mixed Method Evaluation of the RISE Communities Program.International journal of environmental research and public health · 2026Article
- Short-term lagged exposure to ambient air pollutants and hospitalization costs among AMI patients: health-economic evidence from a low-pollution Chinese city with DRG/DIP standardized medical payment.Frontiers in public health · 2026Article
- Xenobiotic Toxicants and Particulate Matter: Effects, Mechanisms, Impacts on Human Health, and Mitigation Strategies.Journal of xenobiotics · 2025Review
- Targeting Cardiotoxicity Induced by Environmental Toxins: The Role of Natural Products.Cardiovascular toxicology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Air pollution is a global environmental health hazard associated with elevated cardiovascular morbidity and mortality. Emerging evidence suggests that exposure to various air pollutants, specifically particulate matter (PM), ultrafine particulate matter (UFPM), and diesel exhaust particles, may exacerbate myocardial ischemia-reperfusion (I/R) injury. PM exposure can directly impair cardiomyocyte survival under ischemic conditions by inducing inflammation, oxidative stress, apoptosis, and dysregulation of non-coding RNAs. Moreover, exposure to PM, UFPM, and diesel exhaust particles can increase infarct size, worsen cardiac function, and exacerbate inflammation, oxidative stress and mitochondrial dysfunction in I/R injury. Evidence indicates that the severity of these effects depends on the specific pollutant, exposure duration, and animal model used. In clinical studies, long-term exposure to air pollution, or even high-dose exposure over a short duration, especially to PM2.5 and PM10, was found to be a risk factor for myocardial infarction. Several interventions targeting the pathways involved in air pollution-induced cardiac I/R injury have shown benefits in preclinical studies, including Cyclosporin A, vanillic acid, and β1-adrenoreceptor antagonists, TRPV1 antagonists, GSK-3β inhibitor, and indomethacin. This review comprehensively summarizes the detrimental impacts of air pollutants on cardiac I/R injury from in vitro and in vivo reports to preclinical investigations, highlighting the complex interplay between pollutant type, exposure duration, and cardiovascular outcomes. The detrimental impact of air pollution through multiple pathways, including oxidative stress, inflammation, mitochondrial dysfunction, and apoptosis on cardiac I/R injury is also discussed, emphasizing the urgence for targeted interventions and public health strategies to mitigate the cardiovascular consequences of pollutant exposure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.